On October 4, 2024 AbCellera (Nasdaq: ABCL) reported an upcoming poster presentation on its T-cell engager platform at the SITC (Free SITC Whitepaper) 39th Annual Meeting, to be held November 6 to 10 at the George R. Brown Convention Center in Houston, Texas (Press release, AbCellera, OCT 4, 2024, View Source [SID1234647047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on AbCellera’s poster presentation at SITC (Free SITC Whitepaper) are as follows:

Title: Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release
Abstract Number: 1291
Date and Time: Friday, November 8 from 9:00 a.m. to 7:00 p.m. CST
Location: Exhibit Halls A B George R. Brown Convention Center or online at View Source

About AbCellera’s T-Cell Engager Platform

CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the development of T-cell engagers has been limited due to challenges with efficacy and safety. To address these challenges, AbCellera developed a T-cell engager platform that includes novel CD3-binding antibodies to expand the therapeutic window for this modality, costimulatory building blocks to enhance efficacy for difficult-to-treat cancers, and discovery capabilities to broaden the range of T-cell engagers to complex peptide-MHC tumor targets. AbCellera is leveraging its platform to unlock the full potential of this modality and bring potential new cancer medicines to patients.